The Problem
Benzodiazepines calm quickly, but long-term use brings cognitive effects, falls, and dependence that make stopping risky. In 2023, an estimated 24 million Americans used a benzodiazepine, with 20 million using them as prescribed. By 2018, half of patients dispensed an oral benzodiazepine received ≥2 months of medication, durations where dependence is common.
Why It Matters
Stopping suddenly is dangerous. Safer exits require slow, individualized tapers and nonpharmacologic supports, yet coverage, coordination, and time are often missing. Geriatric guidance continues to flag benzodiazepines as potentially inappropriate for many older adults.
Key Takeaways
- Start slow: 5–10% reductions every 2–4 weeks; pause when needed; micro-cuts late.
- Pair taper with support: CBT/CBT-I, sleep hygiene, and skills; address opioid and alcohol risks.
- Coordinate care: document rationale and consider compounded or liquid options for tiny decrements.
Beyond the Mic
This isn’t just pharmacology, it’s infrastructure. When systems pay for therapy, embed pharmacists, and protect follow-up time, patients exit more safely. Equity depends on building corridors out, not just warnings about going in.
Featured Resources
- Tapering Benzodiazepine Medications: A Guide for Patients
- Joint Clinical Practice Guideline on Benzodiazepine Tapering SpringerLink
- AGS Beers Criteria (2023 update): guidance for older-adult prescribing
- U.S. Food and Drug Administration
→ Listen to the full episode on The Transformed Minds for practical scripts and case tips.
Listen to Transformed Minds: Between Risk and Relief: Benzodiazepine Use Disorder in a Fragmented System for a grounded, actionable conversation on reforming addiction care. FULL EPISODE
Stay ready. Stay aware. Stay grounded.
